A Phase 3 interventional study of Inhaled Insulin (Exubera) and Standard of Care in Diabetes Mellitus Type 2, sponsored by Pfizer. Terminated at 64 sites in 7 countries. Open to participants aged 35 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-04-02.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing insulin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, 1 of them phase 3. Insulin · Diabetes Mellitus, Type 2.
Among the 54 studies testing insulin in Diabetes Mellitus, Type 2, this one is the 9th largest by enrollment, is one of 3 that started in 2006, is one of 7 in phase 3, and was the 7th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 54 studies testing insulin in Diabetes Mellitus, Type 2 are open now, in 1 country. Recruiting first, the newest first:
Rutgers, The State University of New Jersey · Sites in United States
Ages 55–80
Ohio State University · Sites in United States
Ages 18+ · Women only
Emory University · Sites in United States
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 35 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 8 · Phase 4 20
First in 1995; this study’s year is marked. 3 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 354 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 60 across the 54 interventional studies. Of the 44 that completed or were terminated, 19 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 54 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
80 studies in Diabetes Mellitus, Type 2 by Pfizer: 2 open now, 3 under way, 3 of them phase 3. Of 77 finished, 39 (51%) have results posted.
Among the 80 studies in Diabetes Mellitus, Type 2 by Pfizer, this one is the 8th largest by enrollment of the 79 interventional ones that give a count, is one of 4 that started in 2006, is one of 9 in phase 3, and was the 5th registered.
Pfizer’s Diabetes Mellitus, Type 2 studies by the year they started, since 1999.
3 of the studies testing insulin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06251635Centre for Addiction and Mental HealthEffects of Antipsychotics on Brain Insulin Action in Females | 2026-12-31 |
| NCT06699810Emory UniversityModeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity | 2027-01 |
| NCT07293715Ohio State UniversityPermissive Versus Strict Intrapartum Glucose Management in Type 1 and Type 2 Diabetes (PRISM) | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 54 studies testing insulin in Diabetes Mellitus, Type 2, from their registry updates:
Among Pfizer’s 80 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
To assess the impact on glucose control by inhaled insulin in patients with type 2 diabetes who are not well controlled on 2 or more oral anti-diabetic agents
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Inhaled insulin plus oral therapy
Drug: Inhaled Insulin (Exubera)
Standard of Care: All licensed diabetes drugs can be prescribed per discretion of investigators
Other: Standard of Care
Addition of inhaled insulin to pre-existing oral diabetes therapy.
Standard of Care: All licensed diabetes drugs can be prescribed per discretion of investigators
Percentage Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24
\[(week 24 value - baseline value)/baseline value\]\*100%
Time frame: 4, 12 and 24 weeks
Percentage of Participants Achieving Glycemic Control by Visit
2 definitions of good glycemic control were used: an HbA1c result of ≤6.5% or ≤7.0%
Time frame: 4, 12 and 24 weeks
Change From Baseline in FEV1 at Week 24 LOCF
Time frame: 24 weeks
| Milestone | Inhaled Insulin | Standard of Care |
|---|---|---|
| Started | 180 | 171 |
| Completed | 146 | 149 |
| Not completed | 34 | 22 |
\[(week 24 value - baseline value)/baseline value\]\*100%
| percentage change | Inhaled Insulin | Standard of Care |
|---|---|---|
| week 4 (n=164 and 158, respectively) | -1.08 ± 0.61 | -0.62 ± 0.55 |
| week 12 (n=159 and 150, respectively) | -2.03 ± 0.97 | -1.37 ± 0.92 |
| week 24 (n=142 and 150, respectively) | -2.02 ± 1.10 | -1.44 ± 1.10 |
| week 24 (LOCF, n=175 and 170, respectively) | -1.94 ± 1.09 | -1.42 ± 1.09 |
2 definitions of good glycemic control were used: an HbA1c result of ≤6.5% or ≤7.0%
| Percentage of participants | Inhaled Insulin | Standard of Care |
|---|---|---|
| HbA1c<=7% at week 4 (n=165 and 158 respectively) | 6.1 | 0.0 |
| HbA1c<=7% at week 12 (n=160 and 150 respectively) | 38.1 | 11.3 |
| HbA1c<=7% at week 24 (n=143 and 150 respectively) | 34.3 | 12.0 |
| HbA1c<=7% at wk-24 LOCF (n=178 & 170 respectively) | 32.0 | 12.9 |
| HbA1c<=6.5% at week 4 (n=165 and 158 respectively) | 0.6 | 0.0 |
| HbA1c<=6.5% at week 12 (n=160 &150 respectively) | 15.6 | 4.7 |
| HbA1c<=6.5% at week 24 (n=143 &150 respectively) | 18.2 | 6.0 |
| HbA1c<=6.5% at wk-24 LOCF(n=178 &170 respectively) | 15.2 | 5.9 |
| Liter | Inhaled Insulin | Standard of Care |
|---|---|---|
| Change From Baseline in FEV1 at Week 24 LOCF | -0.27 ± 9.85 | -0.08 ± 0.61 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Inhaled Insulin | — | 8/180 (4.4%) | 123/180 (68.3%) |
| Standard of Care | — | 6/171 (3.5%) | 98/171 (57.3%) |
| Event | Inhaled Insulin | Standard of Care |
|---|---|---|
| Coronary artery diseaseCardiac disorders | 0/180 | 1/171 |
| Myocardial infarctionCardiac disorders | 0/180 | 1/171 |
| Pancreatitis acuteGastrointestinal disorders | 0/180 | 1/171 |
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 0/180 | 1/171 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/180 | 1/171 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/180 | 1/171 |
| Transient ischaemic attackNervous system disorders | 0/180 | 1/171 |
| Acute myocardial infarctionCardiac disorders | 1/180 | 0/171 |
| Cardiac failureCardiac disorders | 1/180 | 0/171 |
| Oedema peripheralGeneral disorders | 1/180 | 0/171 |
| Event | Inhaled Insulin | Standard of Care |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 118/180 | 98/171 |
| CoughRespiratory, thoracic and mediastinal disorders | 10/180 | 2/171 |
| NasopharyngitisInfections and infestations | 8/180 | 4/171 |
| TremorNervous system disorders | 8/180 | 5/171 |
| InfluenzaInfections and infestations | 6/180 | 7/171 |
| Urinary tract infectionInfections and infestations | 7/180 | 6/171 |
| AstheniaGeneral disorders | 5/180 | 6/171 |
| HeadacheNervous system disorders | 2/180 | 6/171 |
| DizzinessNervous system disorders | 6/180 | 3/171 |
| Upper respiratory tract infectionInfections and infestations | 5/180 | 5/171 |
| Age, Customized(participants) | Inhaled Insulin | Standard of Care | Total |
|---|---|---|---|
| <18 years | 0 | 0 | 0 |
| Between 18 and 44 years | 12 | 6 | 18 |
| Between 45 and 64 years | 112 | 113 | 225 |
| >=65 years | 56 | 52 | 108 |
| Sex: Female, Male(Participants) | Inhaled Insulin | Standard of Care | Total |
|---|---|---|---|
| Female | 76 | 80 | 156 |
| Male | 104 | 91 | 195 |
Ran from Mar 2006 to primary completion in Feb 2008, 23 months.
Results were first posted in Aug 2009, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin